Blegen H - Search Results

1

A cell cycle study of human mammary epithelial cells.

Larsson O, Blegen H, Wejde J, Zetterberg A. Larsson O, et al. Among authors: blegen h. Cell Biol Int. 1993 Jun;17(6):565-71. doi: 10.1006/cbir.1993.1100. Cell Biol Int. 1993. PMID: 8348115

2

Requirement for mevalonate in the control of proliferation of human breast cancer cells.

Wejde J, Blegen H, Larsson O. Wejde J, et al. Among authors: blegen h. Anticancer Res. 1992 Mar-Apr;12(2):317-24. Anticancer Res. 1992. PMID: 1580550

3

Inhibitory effect of mevalonate on the EGF mitogenic signaling pathway in human breast cancer cells in culture.

Larsson O, Blegen H. Larsson O, et al. Among authors: blegen h. Cancer Biochem Biophys. 1994 Oct;14(3):193-200. Cancer Biochem Biophys. 1994. PMID: 7728740

4

Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells.

Larsson O, Blegen H. Larsson O, et al. Among authors: blegen h. Anticancer Res. 1993 Jul-Aug;13(4):1075-9. Anticancer Res. 1993. PMID: 8352528

5

Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.

Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M, Zickert P, Höög A, Larsson O. Carlberg M, et al. Among authors: blegen h. J Biol Chem. 1996 Jul 19;271(29):17453-62. doi: 10.1074/jbc.271.29.17453. J Biol Chem. 1996. PMID: 8663239 Free article.

6

Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc.

Dricu A, Wang M, Hjertman M, Malec M, Blegen H, Wejde J, Carlberg M, Larsson O. Dricu A, et al. Among authors: blegen h. Glycobiology. 1997 Jul;7(5):625-33. doi: 10.1093/glycob/7.5.625. Glycobiology. 1997. PMID: 9254045

7

DNA amplifications and aneuploidy, high proliferative activity and impaired cell cycle control characterize breast carcinomas with poor prognosis.

Blegen H, Will JS, Ghadimi BM, Nash HP, Zetterberg A, Auer G, Ried T. Blegen H, et al. Anal Cell Pathol. 2003;25(3):103-14. doi: 10.1155/2003/491362. Anal Cell Pathol. 2003. PMID: 12775914 Free PMC article.

8

Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties.

Kanter L, Blegen H, Wejde J, Lagerlöf B, Larsson O. Kanter L, et al. Among authors: blegen h. Melanoma Res. 1995 Oct;5(5):345-50. doi: 10.1097/00008390-199510000-00007. Melanoma Res. 1995. PMID: 8541725

9

Relationship between oncogene amplification, aneuploidy and altered expression of p53 in breast cancer.

Latham C, Maner S, Blegen H, Eriksson E, Zickert P, Auer G, Zetterberg A. Latham C, et al. Among authors: blegen h. Int J Oncol. 1996 Feb;8(2):359-65. doi: 10.3892/ijo.8.2.359. Int J Oncol. 1996. PMID: 21544369

10

Short exposures to tunicamycin induce apoptosis in SV40-transformed but not in normal human fibroblasts.

Carlberg M, Dricu A, Blegen H, Kass GE, Orrenius S, Larsson O. Carlberg M, et al. Among authors: blegen h. Carcinogenesis. 1996 Dec;17(12):2589-96. doi: 10.1093/carcin/17.12.2589. Carcinogenesis. 1996. PMID: 9006093

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters